At Celgene, our commitment to changing the course of human health extends to those living in developed nations and those living in developing parts of the world.
 |
Access AcceleratedAccess Accelerated is a partnership of over 20 biopharmaceutical companies, including Celgene, developing innovative and sustainable solutions to improve access to treatment and care for noncommunicable diseases (NCDs) — such as cancer — in low- and middle-income countries. |
 |
Celgene Cancer Care Links?Celgene Cancer Care Links? is a grant program to support cancer healthcare capacity building in resource-constrained countries around the world. |
 |
Building Healthcare Capacity for Patients in Africa: AMPATHFor several years, Celgene has worked with Indiana University, Moi University School of Medicine and Moi Teaching and Referral Hospital (MTRH) in Eldoret, Kenya, and a consortium of North American academic health centers to deliver health services, conduct health research, and develop leaders in healthcare for both North America and Africa. The institutional partners are collectively named the Academic Model Providing Access to Healthcare (AMPATH). |
 |
Neglected Tropical DiseasesCGH is screening our diverse chemical library against the pathogens for neglected tropical diseases. |
 |
R&D for Neglected Tropical DiseasesCollaborating closely with disease experts from non- profit and academic institutions around the globe, CGH has utilized the diverse, drug-like properties of the company’s library of more than 400,000 compounds. |